Posted 3/12/2024, 5:46:00 PM
Global Alexipharmic Drugs Market to Grow at 5% CAGR through 2034, Driven by Opioid Antidotes and Parenteral Administration
- Global alexipharmic drugs market size was $3.7 billion in 2023, expected to reach $6.45 billion by 2034 with a CAGR of 5.17%
- Opioid overdose segment accounted for highest revenue share in 2023 due to rising opioid abuse and need for antidotes
- Parenteral route of administration segment had the highest revenue share in 2023 due to preference for reliable, rapid drug delivery
- North America and Europe together accounted for over 60% revenue share of the global market
- Key companies in the market include Pfizer, Novartis, GlaxoSmithKline, Johnson & Johnson, Sanofi, Merck, and Eli Lilly